Conference Coverage
Conference Coverage
VIDEO: Biosimilars show promise and progress
LAS VEGAS - Although none are yet available, biosimilar molecules are "very comparable” to the reference molecules, Dr. Bruce E. Strober says....
Conference Coverage
Optimize anti–TNF-alpha therapy for psoriasis
Anti–TNF-alpha medications have shown effectiveness for psoriasis, but ongoing issues include optimizing therapy, managing treatment in special...
Conference Coverage
VIDEO: IL-23 inhibitors on the upswing
LAS VEGAS
Conference Coverage
Include quality of life measures in evaluating treatment success of psoriasis
No matter what the disease, physician judgment of disease severity correlates poorly with the patient’s quality of life, Dr. Joel Gelfand said...
Conference Coverage
Biologic-naive psoriasis patients get biggest boost with treatment
LAS VEGAS - Biologic-naive psoriasis patients had stronger responses to treatment than those who were previously treated and switched from one...
Conference Coverage
Study offers reassuring data on certolizumab use in pregnancy
VIENNA – Consider off-label certolizumab in women with psoriasis who need a biologic and are pregnant or planning to become so.
Conference Coverage
What good are biosimilars if patients won’t use them?
BOSTON – The only meaningful measure of the success of biosimilar drugs for arthritis is whether patients use them.
Conference Coverage
Close monitoring of psoriasis patients can delay PsA onset
NEWPORT BEACH, CALIF. – A patient with psoriasis can develop crippling psoriatic arthritis (PsA) within 5 to 10 years of diagnosis, but monitoring...
Conference Coverage
Tildrakizumab for psoriasis scores high marks in phase III
VIENNA – Tildrakizumab, a novel biologic for moderate to severe psoriasis, showed favorable efficacy and safety outcomes in two pivotal phase III...
Conference Coverage
Secukinumab for psoriasis at 4 years: undiminished efficacy and safety
VIENNA – Secukinumab showed reassuring safety with no drop-off in efficacy for psoriasis after 4 years of treatment.